myocardial infarction or coronary death, a 24% decrease in the need for coronary bypass surgery, and a 17% decrease in the rate of fatal or nonfatal stroke. 2 The recently reported results of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin (20 mg per day) show that even patients with moderate risk can benefit very substantially from statin treatment. 3 The study included only patients with initial LDL levels below 130 mg per deciliter (median, 108 mg per deciliter) and achieved on-treatment levels averaging 55 mg per deciliter. Statin treatment decreased all-cause mortality by 20%, the primary end point of combined cardiovascular events by 44%, myocardial infarction by 54%, and stroke by 48%. What do we have in our medical bag that can match that? Moreover, the statins are probably safer than aspirin, and they are cost effective. 4 Finally, there is good reason to believe that even more striking results may be seen when we start treating hypercholesterolemia in patients at an earlier age. 
Eculizumab for Atypical Hemolytic-Uremic Syndrome
To the Editor: Atypical hemolytic-uremic syndrome is a disease of uncontrolled complement activation associated with a high mortality rate, and most cases progress to end-stage renal disease. 1 About 50% of patients with this syndrome carry mutations in genes encoding complement proteins. 2 Complement inhibition has been suggested for the treatment of atypical hemolyticuremic syndrome, 3 but currently no data on this treatment option are available. We report on a case of atypical hemolytic-uremic syndrome that was successfully treated with eculizumab, a humanized monoclonal antibody that blocks complement activity by cleavage of the complement protein C5, thereby preventing the generation of the inflammatory peptide C5a and the cytotoxic membrane-attack complex, C5b-9. Eculizumab has been approved for the treatment of paroxysmal nocturnal hemoglobinuria. 4 End-stage renal disease due to atypical hemolytic-uremic syndrome developed in a woman at 25 years of age. At 30 years of age, after 5 years of undergoing dialysis, she received a cadaveric renal transplant. Five weeks after transplantation, atypical hemolytic-uremic syndrome recurred and led to the loss of transplant function despite 18 plasma exchanges. The patient underwent dialysis for another 7 years until she received a second
Figure 1 (facing page). Pathological Findings and Laboratory Values.
In Panel A, elastic Masson's trichrome stain shows thrombotic microangiopathy with numerous intracapillary erythrocytes. The inset shows magnification of the area with red-cell fragments. In Panel B, hematoxylin and eosin stain shows hyaline microthrombi that occlude glomerular capillaries (arrowheads). In Panel C, immunostaining for complement protein C4d was positive in glomerular capillaries and preglomerular arterioles (arrowheads), indicating an activation of the complement system. C4d staining of peritubular capillaries (PTC), an indicator of humoral rejection, was negative. Panel D shows the time course of the platelet count and laboratory values used to determine the occurrence of hemolysis in the patient who underwent renal transplantation (eculizumab was administered at 0 days). When atypical hemolytic-uremic syndrome was diagnosed (arrowhead), tacrolimus was discontinued and plasma exchange was performed four times (vertical black bars indicate treatments). Despite this treatment, atypical hemolyticuremic syndrome was aggravated, as indicated by the progressive decrease in platelets to 35,000 per cubic millimeter and the deterioration of transplant function indicated by an increase in the creatinine level to 1.5 mg per deciliter. A single dose of 600 mg of eculizumab was administered (arrow), and measurements of total complement activity (data not shown) showed that eculizumab completely blocked the complement system. After treatment with eculizumab, haptoglobin levels normalized after 8 days, the platelet count increased, and the creatinine level decreased, indicating recovery of transplant function. cadaveric transplant at 37 years of age. Six weeks after the second transplantation, atypical hemolytic-uremic syndrome again recurred. The onset of atypical hemolytic-uremic syndrome may have been associated with the additional use of tacrolimus, which the patient received after three episodes of cellular rejection developed.
Genetic analysis revealed a novel heterozygous missense mutation in exon 10, codon 475 (Y475S), of the gene encoding complement factor H. This missense mutation leads to a substitution of a serine by a tyrosine that belongs to the highly conserved residues of the factor H protein sequence; this sequence may be responsible for the 
